Skip to main content

Table 2 Comparisons of whole CBF outcomes in ipsilateral MCA territory of carotid artery system stenosis between NBP and placebo groups

From: DL-3-n-butylphthalide improves cerebral hypoperfusion in patients with large cerebral atherosclerotic stenosis: a single-center, randomized, double-blind, placebo-controlled study

Number of ROIs with rCBF amelioration/deteriorationGroupDeterioration
n (%)
Stablization
n (%)
Amelioration
n (%)
χ2P values
≥1NBP10 (20.8%)23 (47.9%)15 (31.2%)2.0490.359
Control15 (32.6%)21 (45.7%)10 (21.7%)
≥2NBP1 (2.1%)37 (77.1%)10 (20.8%)11.3620.003
Control12 (26.1%)27 (58.7%)7 (15.2%)
≥3NBP1 (2.1%)40 (83.3%)7 (14.6%)8.7990.012
Control10 (21.7%)31 (67.4%)5 (10.9%)
≥4NBP0 (0.0%)43 (89.6%)5 (10.4%)6.4410.015
Control5 (10.9%)39 (84.8%)2 (4.3%)
  1. Definitions of whole CBF outcomes were according to the number of ROIs with rCBF amelioration/deterioration. CBF cerebral blood flow, MCA middle cerebral artery, NBP Dl-3-butylphthalide, ROI regions of interest, rCBF regional CBF